Close Menu

Tissue-Based Testing

News on immunohistochemistry and other tissue-based testing methods.

The extended deal covers multiple blood cancer and solid tumor indications and will leverage several HalioDx technologies and approaches.

The firm hopes for a decision from the FDA later this year for its breast cancer drug candidate alpelisib, following results from a late-stage trial.

Kiyatec's cell-based assays model and predict patient therapeutic response to drive cancer drug development and potentially guide treatment.

The test uses multiplex PCR fragment analysis with Promega-designed five-mononucleotide repeat markers to detect the MSI-high phenotype within tumor tissues.

In order to be eligible for the drug, patients must have NTRK fusions, which may be determined via various tests including NGS and FISH.